• In the past week, Intuitive Surgical reported strong first-quarter 2026 results, with revenue and earnings per share beating expectations, lifted by higher da Vinci procedure volumes, more system placements, and an upgraded full-year procedure growth outlook alongside anticipated margin expansion despite tariff pressures.
• The company also unveiled over 100 software and hardware enhancements for its da Vinci 5 ecosystem, signaling a deeper push into digital, connectivity, and force-feedback capabilities that could influence how surgeons use and hospitals evaluate robotic-assisted surgery platforms.
• We’ll now examine how the raised da Vinci procedure growth outlook may influence Intuitive Surgical’s existing investment narrative and risk profile.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Intuitive Surgical Investment Narrative Recap

To own Intuitive Surgical, you need to believe robotic-assisted procedures will keep gaining share within minimally invasive surgery, supporting recurring instrument and service revenue from a growing installed base. Right now, the key near term catalyst is continued da Vinci procedure growth, while a major risk is rising tariff and trade uncertainty that could pressure margins. The latest results and raised procedure outlook bolster the catalyst, but do not remove the margin risk from higher tariffs.

The most relevant recent announcement is the rollout of more than 100 software and hardware enhancements for the da Vinci 5 ecosystem, including expanded connectivity and force feedback capabilities. These upgrades tie directly into the procedure growth story by potentially making the platform more attractive for surgeons and hospitals, which could support higher utilization on existing systems and influence future upgrade decisions if clinical and workflow benefits are validated.

Yet even with strong procedure momentum, investors should be aware that concentrated tariff exposure could still...

Intuitive Surgical's narrative projects $13.4 billion revenue and $3.7 billion earnings by 2028. This requires 13.5% yearly revenue growth and about a $1.1 billion earnings increase from $2.6 billion today.

Uncover how Intuitive Surgical's forecasts yield a $611.82 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this quarter, assuming revenue could reach about US$16.1 billion and earnings around US$4.9 billion, while also warning that rising trade tensions and new tariffs might materially squeeze margins. This upbeat view contrasts with more measured expectations and may shift again after the latest procedure and da Vinci 5 updates, reminding you that reasonable investors can read the same numbers very differently.

Explore 12 other fair value estimates on Intuitive Surgical - why the stock might be worth as much as 43% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance.

No Opportunity In Intuitive Surgical?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 53 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.